Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed/refractory chronic lymphocytic leukemia

Daniel Park, Alec M. Chan-Golston, Yueqi Yan, Farris Al-Manaseer, Mojtaba Akhtari

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalJournal of Chemotherapy
DOIs
StateAccepted/In press - 2024

ASJC Scopus Subject Areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Keywords

  • Acalabrutinib
  • BTKi
  • Bruton tyrosine kinase inhibitor
  • relapsed/refractory chronic lymphocytic leukemia

Cite this